Clinical-stage biopharmaceutical company developing immunotherapies for autoimmune and inflammatory diseases.
Alpine Immune Sciences, Inc., headquartered in Seattle, Washington, is a clinical-stage biopharmaceutical company specializing in the research and development of protein-based immunotherapies. The company is dedicated to advancing treatments for a range of conditions, including cancer, autoimmune disorders, and inflammatory diseases. Alpine's innovative pipeline features several promising candidates, including ALPN-101, an antagonist targeting inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28), aimed at autoimmune and inflammatory conditions.
Additionally, Alpine is developing ALPN-202, a novel dual checkpoint inhibitor and conditional CD28 costimulator designed to enhance anti-tumor immune responses in cancer therapy. The company's portfolio also includes ALPN-303, a dual antagonist targeting B cell cytokines, intended for the treatment of autoimmune and inflammatory diseases mediated by B cells.
Alpine Immune Sciences collaborates with industry leaders such as AbbVie Ireland Unlimited Company for the development of ALPN-101, highlighting its commitment to advancing therapeutic solutions through strategic partnerships. Moreover, the company has partnered with Adaptimmune Therapeutics plc to explore next-generation SPEAR T cell products, underscoring its focus on leveraging cutting-edge technologies to innovate in the field of immunotherapy.
Founded in 2007, Alpine Immune Sciences has established itself as a leader in biopharmaceutical innovation, driven by a mission to harness the potential of protein-based therapies to transform patient care. With a strong emphasis on scientific excellence and collaboration, Alpine continues to expand its pipeline and pursue groundbreaking treatments that aim to improve outcomes and quality of life for patients worldwide.